Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Open Access
- 9 February 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 18 (1), 1-11
- https://doi.org/10.1186/s13058-015-0661-5
Abstract
Despite significant advances in early detection and treatment, breast cancer still remains a major cause of morbidity and mortality for women. Our understanding of the molecular heterogeneity of the disease has significantly expanded over the past decade and the role of cell cycle signaling in both breast cancer oncogenesis and anti-estrogen resistance has gained increasing attention. The mammalian cell cycle is driven by a complex interplay between cyclins and their associated cyclin-dependent kinase (CDK) partners, and dysregulation of this process is one of the hallmarks of cancer. Despite this, initial results with broadly acting CDK inhibitors were largely disappointing. However, recent preclinical and phase I/II clinical studies using a novel, oral, reversible CDK4/6 inhibitor, palbociclib (PD-0332991), have validated the role of CDK4/6 as a potential target in estrogen receptor-positive (ER+) breast cancers. This review highlights our current understanding of CDK signaling in both normal and malignant breast tissues, with special attention placed on recent clinical advances in inhibition of CDK4/6 in ER+ disease.Keywords
This publication has 81 references indexed in Scilit:
- A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancerBreast Cancer Research and Treatment, 2012
- CDK4: A Key Player in the Cell Cycle, Development, and CancerGenes & Cancer, 2012
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer CellsCancer Cell, 2011
- Distinct Interactions Select and Maintain a Specific Cell FateMolecular Cell, 2011
- Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)British Journal of Cancer, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Nuclear Cyclin D1/CDK4 Kinase Regulates CUL4 Expression and Triggers Neoplastic Growth via Activation of the PRMT5 MethyltransferaseCancer Cell, 2010
- Transcriptional role of cyclin D1 in development revealed by a genetic–proteomic screenNature, 2010
- Positive feedback of G1 cyclins ensures coherent cell cycle entryNature, 2008